Literature DB >> 19500131

Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia.

Lewin Eisele1, Robert Prinz, Ludger Klein-Hitpass, Holger Nückel, Kerstin Lowinski, Jürgen Thomale, Lars C Moeller, Ulrich Dührsen, Jan Dürig.   

Abstract

The objective of this study was to confirm previous results regarding the differential expression and prognostic significance of the circadian gene CRY1 in chronic lymphocytic leukemia (CLL) patients and its relationship with the expression of other circadian genes and well-established prognostic markers. We also aimed to investigate whether the peripheral circadian machinery may be deregulated in CLL cells. The expression of CRY1, PER1, and PER2 was determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in 116 CLL patients. The expression at sequential time points over a 24-h period was measured in six CLL patients and six normal donors. We confirmed the differential expression of CRY1 in ZAP-70(+)/CD38(+) and ZAP-70(-)/CD38(-) CLL samples. Subgroups formed according to CRY1 expression levels differed significantly in time to treatment. This difference was even more pronounced for subgroups stratified by a CRY1 : PER2 expression ratio and the ratio was an independent prognostic marker in a multivariate model. Furthermore, our data indicate disturbances in the periodic expression of circadian genes in CLL cells. Because of their role in the expression of cell cycle-related and DNA-damage response genes, we suggest that the deregulated expression of circadian genes may be linked to the molecular pathogenesis of CLL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500131     DOI: 10.1111/j.1600-0609.2009.01287.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  21 in total

1.  Family-based association studies for next-generation sequencing.

Authors:  Yun Zhu; Momiao Xiong
Journal:  Am J Hum Genet       Date:  2012-06-08       Impact factor: 11.025

Review 2.  Circadian rhythms and cancer.

Authors:  Sigal Gery; H Philip Koeffler
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

3.  Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia.

Authors:  Sobia Rana; Mustafa Munawar; Adeela Shahid; Meera Malik; Hafeez Ullah; Warda Fatima; Shahida Mohsin; Saqib Mahmood
Journal:  Mol Biol Rep       Date:  2013-11-05       Impact factor: 2.316

4.  Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation.

Authors:  Sarah C Roode; Daniel Rotroff; Anne C Avery; Steven E Suter; Dorothee Bienzle; Joshua D Schiffman; Alison Motsinger-Reif; Matthew Breen
Journal:  Chromosome Res       Date:  2015-06-03       Impact factor: 5.239

Review 5.  Circadian gene variants in cancer.

Authors:  Nicole M Kettner; Chinenye A Katchy; Loning Fu
Journal:  Ann Med       Date:  2014-06-05       Impact factor: 4.709

Review 6.  Understanding the significance of biological clock and its impact on cancer incidence.

Authors:  Shalie Malik; James Stokes Iii; Upender Manne; Rajesh Singh; Manoj K Mishra
Journal:  Cancer Lett       Date:  2021-12-11       Impact factor: 8.679

7.  Circadian rhythm and its role in malignancy.

Authors:  Sobia Rana; Saqib Mahmood
Journal:  J Circadian Rhythms       Date:  2010-03-31

Review 8.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

9.  Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia.

Authors:  Maher Hanoun; Lewin Eisele; Masako Suzuki; John M Greally; Andreas Hüttmann; Semra Aydin; René Scholtysik; Ludger Klein-Hitpass; Ulrich Dührsen; Jan Dürig
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

10.  Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival.

Authors:  Ti'ara L Griffen; Eric B Dammer; Courtney D Dill; Kaylin M Carey; Corey D Young; Sha'Kayla K Nunez; Adaugo Q Ohandjo; Steven M Kornblau; James W Lillard
Journal:  BMC Med Genomics       Date:  2021-06-29       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.